US Bancorp
GALT icon

US Bancorp’s Galectin Therapeutics GALT Stock Holding History

US Bancorp’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-118,921
Closed -$397K – 3628
2017
Q4 		$397K Hold
118,921
– – ﹤0.01% 1541
2017
Q3 		$254K Hold
118,921
– – ﹤0.01% 1747
2017
Q2 		$293K Hold
118,921
– – ﹤0.01% 1643
2017
Q1 		$274K Buy
118,921
+28,087
+31% +$42.3K ﹤0.01% 1661
2016
Q4 		$89K Hold
90,834
– – ﹤0.01% 2171
2016
Q3 		$103K Hold
90,834
– – ﹤0.01% 2063
2016
Q2 		$134K Hold
90,834
– – ﹤0.01% 1869
2016
Q1 		$130K Hold
90,834
– – ﹤0.01% 1881
2015
Q4 		$149K Hold
90,834
– – ﹤0.01% 1841
2015
Q3 		$213K Hold
90,834
– – ﹤0.01% 1703
2015
Q2 		$248K Buy
+90,834
New +$274K ﹤0.01% 1671

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return
EGI
EAM Global Investors Solana Beach, California $34.8M AUM 275.91% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return

US Bancorp's GALT Position: Q1 2018 in Review

US Bancorp sold out of Galectin Therapeutics (GALT) in Q1 2018, closing a stake of 118,921 shares — an estimated $397K sold.

US Bancorp first reported a position in GALT in Q2 2015 and held it in 11 quarters. The position peaked at $397K in Q4 2017. 62 funds tracked by Wall St. Rank hold GALT as of Q1 2018.

  • US Bancorp reported no remaining Galectin Therapeutics position as of Q1 2018 after selling out during the quarter.
  • US Bancorp sold 118,921 Galectin Therapeutics shares in Q1 2018, an estimated $397K.
  • US Bancorp first reported a position in Galectin Therapeutics in Q2 2015 and held it in 11 quarters.
  • US Bancorp's Galectin Therapeutics position peaked at $397K in Q4 2017.
  • 62 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2018.

Based on US Bancorp's 13F filing for Q1 2018, filed 8 May 2018.